Fagron publishes annual report 2023
14 Mars 2024 - 6:30PM
Fagron publishes annual report 2023
Regulated informationNazareth (Belgium)/Rotterdam (The
Netherlands), 14 March 2024 – 6:30 PM CET
Fagron publishes annual report 2023
Fagron, the leading global player in pharmaceutical compounding,
today publishes its annual report 2023. Discussion of the annual
report and the approval of the financial statements will be put on
the agenda of the annual general meeting of shareholders scheduled
for 13 May 2024.
The annual report is available in the official Dutch version and
in English translation on Fagron’s website.
Further informationKaren BergGlobal Investor
Relations ManagerTel. +31 6 53 44 91 99karen.berg@fagron.com
About FagronFagron is a leading global company
active in pharmaceutical compounding, focusing on delivering
personalized medicine to hospitals, pharmacies, clinics, and
patients in more than 30 countries around the world.
Belgian company Fagron NV has its registered office in Nazareth
and is listed on Euronext Brussels and Euronext Amsterdam under the
ticker symbol ‘FAGR’. Fagron’s operational activities are managed
by the Dutch company Fagron BV, which is headquartered in
Rotterdam.
In the event of differences between the English translation and
the Dutch original of this press release, the latter prevails.
- Fagron publishes annual report 2023
Fagron NV (EU:FAGR)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Fagron NV (EU:FAGR)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
